Normothermic machine perfusion versus static cold storage for liver transplantation: a systematic review and meta-analysis.

Acta Cir BrasSep 11, 2026 (epub)
Clinical ResearchGeneral SurgeryGastroenterology

Miguel Lucas Silva Valente, Angela Claudia Paixão Soares de Magalhães, Hercules Magalhães Olivense do Carmo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of normothermic machine perfusion (NMP) versus static cold storage (SCS) in liver transplantation, involving 630 recipients across five studies. NMP significantly reduced the incidence of early postoperative complications compared to SCS, with a risk ratio of 0.60 (95%CI 0.47-0.75; p < 0.0001).

Key findings

  • NMP reduced early postoperative complications with a risk ratio of 0.60 compared to SCS.
  • The relative risk reduction for complications with NMP was 40%.
  • No significant effect modification was found by study design or donor characteristics.
  • Between-study heterogeneity was negligible (I2 = 0%).

Why it matters

Understanding the advantages of NMP over SCS is crucial for clinicians involved in liver transplantation, as it may lead to improved patient outcomes and expanded use of marginal donor organs.

Source

PubMed · PMID 42752723

Published in Acta Cir Bras. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.